Ma H, Yan QZ, Ma JR, Li DF, Yang JL. Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies. World J Gastroenterol 2024; 30(10): 1295-1312 [PMID: 38596493 DOI: 10.3748/wjg.v30.i10.1295]
Corresponding Author of This Article
Qing-Zhu Yan, MBBS, MD, Associate Professor, Department of Ultrasound Medicine, The Second Hospital of Jilin University. No. 218 Ziqiang Street, Nanguan District, Changchun 130000, Jilin Province, China. yanqingzhu@jlu.edu.cn
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Mar 14, 2024; 30(10): 1295-1312 Published online Mar 14, 2024. doi: 10.3748/wjg.v30.i10.1295
Overview of the immunological mechanisms in hepatitis B virus reactivation: Implications for disease progression and management strategies
Hui Ma, Qing-Zhu Yan, Jing-Ru Ma, Dong-Fu Li, Jun-Ling Yang
Hui Ma, Jing-Ru Ma, Department of Clinical Laboratory, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China
Qing-Zhu Yan, Department of Ultrasound Medicine, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China
Dong-Fu Li, Digestive Diseases Center, Department of Hepatopancreatobiliary Medicine, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China
Jun-Ling Yang, Department of Respiratory and Critical Care Medicine, The Second Hospital of Jilin University, Changchun 130000, Jilin Province, China
Author contributions: Ma H contributed to supervision, methodology, formal analysis, and writing-original draft; Yan QZ and Ma JR contributed to validation and data curation; Li DF contributed to resources and writing-review and editing; Yang JL contributed to conceptualization, writing-review, and editing; all authors approved the final submitted version of this manuscript.
Conflict-of-interest statement: The authors declare that there is no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Qing-Zhu Yan, MBBS, MD, Associate Professor, Department of Ultrasound Medicine, The Second Hospital of Jilin University. No. 218 Ziqiang Street, Nanguan District, Changchun 130000, Jilin Province, China. yanqingzhu@jlu.edu.cn
Received: November 17, 2023 Peer-review started: November 17, 2023 First decision: December 14, 2023 Revised: December 25, 2023 Accepted: January 24, 2024 Article in press: January 24, 2024 Published online: March 14, 2024 Processing time: 117 Days and 23.5 Hours
Core Tip
Core Tip: Hepatitis B virus (HBV) reactivation poses a substantial clinical challenge, demanding a nuanced understanding of immunological mechanisms for effective management. This comprehensive review navigates the intricate landscape of HBV reactivation, spotlighting the delicate balance between host immune responses and viral factors. Emphasis is placed on the roles of T cells, natural killer cells, and antigen-presenting cells in disease progression, alongside the repercussions on severity, hepatic flares, liver fibrosis, and hepatocellular carcinoma. Critical analysis of management strategies, spanning anti-viral and immunomodulatory approaches, informs evidence-based practices. Prophylactic anti-viral therapy’s role during immunosuppression and the potential of innovative immunotherapies are explored, contributing significantly to informed disease management and improved patient outcomes.
